? San Diego-based Turning Point Therapeutics has laid out terms for its IPO, planning to sell 7.4 million shares at a range of $16 to $18 a share. Renaissance Capital reports that insiders expect to take about 40% of a total of around $125 million, which would give the oncology biotech a valuation of more than $500 million. They’ll sell shares under the $TPTX symbol. The biotech is developing a pipeline of tyrosine kinase inhibitors.
? Hookipa Biotech is shooting for $100 million in an upsized IPO, having announced a price range of $14 to $16 fo